Cargando…

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

The aim of this study was to ascertain if oestrogen receptor (ER) status predicts for pathological complete response (pCR) to neoadjuvant chemotherapy in operable breast cancer, and the effects of pCR on survival. Using a single-institution database, 435 patients were identified, who received neoadj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ring, A E, Smith, I E, Ashley, S, Fulford, L G, Lakhani, S R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409783/ https://www.ncbi.nlm.nih.gov/pubmed/15558072 http://dx.doi.org/10.1038/sj.bjc.6602235

Ejemplares similares

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
por: Delpech, Y, et al.
Publicado: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Hong, Jin, et al.
Publicado: (2021)

Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
por: Zhao, Fangyuan, et al.
Publicado: (2023)

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
por: Tanioka, M, et al.
Publicado: (2010)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers
por: Jonasson, Jon G, et al.
Publicado: (2016)

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
por: Pataer, Apar, et al.
Publicado: (2018)

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Meattini, Icro, et al.
Publicado: (2014)

Soluble and nuclear oestrogen receptor status in human breast cancer in relation to prognosis.
por: Leake, R. E., et al.
Publicado: (1981)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?
por: Savaridas, Sarah L., et al.
Publicado: (2019)

Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
por: Dong, Jie, et al.
Publicado: (2021)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Histopathological and Haemogram Features Correlate with Prognosis in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation without Pathological Complete Response
por: Huang, Yu-Ming, et al.
Publicado: (2022)

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
por: Goorts, Briete, et al.
Publicado: (2017)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alba, Emilio, et al.
Publicado: (2016)

Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Ramírez-Tortosa, César L., et al.
Publicado: (2022)

The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
por: Gao, Siming, et al.
Publicado: (2023)

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Heitz, Florian, et al.
Publicado: (2019)

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety
por: Villanueva, Luis, et al.
Publicado: (2021)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy
por: Ryu, Young Jae, et al.
Publicado: (2018)

Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer
por: Meng, Xiangyu, et al.
Publicado: (2022)

Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Li, Shunying, et al.
Publicado: (2020)

Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
por: Melchior, Nicole M., et al.
Publicado: (2020)

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011)

Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
por: Marinovich, M L, et al.
Publicado: (2013)

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
por: Li, JunJie, et al.
Publicado: (2016)

The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy
por: Nakazawa, Yuko, et al.
Publicado: (2020)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review
por: Lobbes, M. B. I., et al.
Publicado: (2013)

Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2021)

Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
por: Acevedo, Francisco, et al.
Publicado: (2022)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a17meshajgavth13i0gk8dpja9